Teva Announces AUSTEDO® XR (deutetrabenazine) Extended-

U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets



AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 inhibitor for effective...

Related Keywords

Texas , United States , Americans , Dell Faulkingham , Rakesh Jain , Clin Psychopharmacol , National Institute Of Mental Health , Texas Tech University School Of Medicine , Drug Administration , Teva Shared Solutions , Teva Neuroscience Inc , Teva Pharmaceutical Industries Ltd , Understanding How Chorea Affects Health , Us Department Of Health , Human Services , Online Survey Of Patients , National Institute Of Neurological Disorders , Teva Pharmaceuticals , National Alliance On Mental Illness , Teva Pharmaceutical Industries , Senior Vice President , Clinical Professor , Texas Tech University School , Tardive Dyskinesia , Chorea Associated , Release Tablets , Adverse Events , Malignant Syndrome , Melanin Containing Tissues , Adverse Reactions , Prescribing Information , Pharmaceutical Industries , Private Securities Litigation Reform Act , Quarterly Report , Annual Report , Teva Neuroscience , Term Deutetrabenazine Treatment , Sustained Benefits , Open Label Extension , Lindenmayerj P , National Institute , Neurological Disorders , Accessed May , Huntington Disease , Nova Science , From Phenomenology , Mental Illness ,